Posted by Michael Wonder on 01 May 2020
Swiss study sees no link between cancer drug prices and patient benefits
1 May 2020 - New research from the University of Zurich renews calls for more transparency in the way drug prices are determined as more high-priced cancer drugs come on the market.
Prices for cancer drugs have risen steeply in the last few years, straining healthcare systems and triggering debate about how prices are set. According to a report by Swiss public television RTS, the price for reimbursement for cancer-fighting drugs in Switzerland has increased by 54% in the last five years.
In the study published in The Lancet, researchers at the University of Zurich and Harvard Medical School have concluded that price has little to do with the effectiveness of a medicine.
